Survodutide

Uses

Survodutide is a dual glucagon/glucagon-like peptide 1 (GLP1) receptor agonist. Survodutide has demonstrated blood sugar lowering efficacy in a Phase II trial for the treatment of patients with type 2 diabetes and obesity and was associated with clinically meaningful weight loss^[1]. Survodutide is also being studied for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)^[2].

References

[1] BRIAND F, AUGUSTIN R, WESCHE F, et al. 1635-P: Survodutide Weight Loss Is Associated with Changes in Food Preference and Improvement of Dyslipidemia in the Free Choice Diet–Induced Obese Hamster Model[J]. Diabetes, 2024, 33 2. DOI:10.2337/db24-1635-p.
[2] Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis[J]. Journal of Hepatology, 2024, 81 5: Pages 837-846. DOI:10.1016/j.jhep.2024.06.003.